At the news
? BEARISHIMPACT 6/10 6-K filed Jul 9, 2026 at 06:17 ET
AstraZeneca announced that the CARDIO-TTRansform Phase III trial for Wainua (eplontersen) in transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) did not meet the primary composite endpoint of CV mortality and recurrent CV events versus placebo. The drug was generally well tolerated, but adding it to standard of care including a majority on a stabiliser showed no statistically significant benefit. A prespecified monotherapy subgroup showed nominally significant fewer events, while no effect was seen in patients on stabiliser at baseline. The failure is a setback for AZN's pipeline in a large indication, but the stock impact may be moderated by the company's diversified portfolio and the monotherapy signal.
- CARDIO-TTRansform Phase III trial did not meet the primary efficacy endpoint of composite CV mortality and recurrent CV events up to 140 weeks.
- Trial enrolled 1,432 participants across 130 sites in 20 countries, randomised 1:1 to eplontersen 45 mg or placebo.
- 57% of patients in each arm received a stabiliser at baseline; a further 24% in each arm initiated a stabiliser during the trial.
- Prespecified monotherapy subgroup showed nominally significant fewer primary composite events; no treatment effect observed in patients on stabiliser at baseline.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access